Clinical Trial Update: A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study of duvelisib in combination with pembrolizumab in head and neck squamous cell carcinoma was terminated, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Duvelisib (duvelisib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: SecuraBio | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-04-07